JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Elenco Azioni・Alnylam Pharmaceuticals Inc

Search

Alnylam Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

301.71 1.32

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

294.94

Massimo

302.34

Metriche Chiave
By Trading Economics
Entrata	-65M 186M
Vendite	-152M 1.1B
P/E Media del settore	131.842 67.147
EPS	1.25
Margine di Profitto	16.993
Dipendenti	2,500
EBITDA	-152M 145M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+50.75% upside

Dividendi
By Dow Jones
Utili prossimi	30 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.1B 41B
Apertura precedente	300.39
Chiusura precedente	301.71

Notizie sul Sentiment di mercato

By Acuity

16%

84%

29 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

256.565 / 269.81 Supporto e resistenza

Alnylam Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 mag 2026, 22:17 UTC

Utili

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mag 2026, 23:47 UTC

Utili

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mag 2026, 23:40 UTC

Discorsi di Mercato

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mag 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

4 mag 2026, 22:39 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mag 2026, 22:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mag 2026, 22:26 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mag 2026, 22:02 UTC

Utili

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mag 2026, 22:00 UTC

Discorsi di Mercato

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mag 2026, 21:52 UTC

Utili

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mag 2026, 21:50 UTC

Utili

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mag 2026, 21:50 UTC

Utili

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mag 2026, 21:49 UTC

Utili

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mag 2026, 21:43 UTC

Utili

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mag 2026, 21:41 UTC

Utili

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mag 2026, 21:40 UTC

Utili

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Confronto tra pari

Modifica del prezzo

Alnylam Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

50.75% in crescita

Previsioni per 12 mesi

Media 449.12 USD 50.75%

Alto 550 USD

Basso 330 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Alnylam Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

16

Acquista

4

Mantieni

0

Vendi

Basato sugli analisti di 20 che hanno fornito valutazioni azionarie a Alnylam Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

256.565 / 269.81Supporto e resistenza

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

29 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Altri titoli del settore

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat